Last reviewed · How we verify

Advancis Pharmaceutical Corporation — Portfolio Competitive Intelligence Brief

Advancis Pharmaceutical Corporation pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Amoxicillin Pulsatile Release Multiparticluate Sprinkle Amoxicillin Pulsatile Release Multiparticluate Sprinkle phase 3 Beta-lactam antibiotic (penicillin) Penicillin-binding proteins (PBPs) Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Advancis Pharmaceutical Corporation:

Cite this brief

Drug Landscape (2026). Advancis Pharmaceutical Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/advancis-pharmaceutical-corporation. Accessed 2026-05-17.

Related